[{"id":"d2d8a1f4-83ff-4a9f-8f76-430436ac978b","acronym":"ALISON","url":"https://clinicaltrials.gov/study/NCT04739527","created_at":"2021-02-04T18:58:55.737Z","updated_at":"2024-07-02T16:35:59.933Z","phase":"Phase 1","brief_title":"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","source_id_and_acronym":"NCT04739527 - ALISON","lead_sponsor":"University Medical Center Groningen","biomarkers":" BIRC5 • CTAG1B • PRAME","pipe":"","alterations":" ","tags":["BIRC5 • CTAG1B • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vididencel (DCP-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-11-28"},{"id":"a1bad84a-eaf6-4a75-9d77-26cdafb7d16d","acronym":"ADVANCE-II","url":"https://clinicaltrials.gov/study/NCT03697707","created_at":"2021-01-18T18:07:22.526Z","updated_at":"2024-07-02T16:36:02.812Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia","source_id_and_acronym":"NCT03697707 - ADVANCE-II","lead_sponsor":"Mendus","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vididencel (DCP-001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-10-10"}]